- Home
- GASS vs YMAB Comparison
GASS vs YMAB Comparison
Compare GASS & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GASS
- YMAB
- Stock Information
- Founded
- GASS 2004
- YMAB 2015
- Country
- GASS Greece
- YMAB United States
- Employees
- GASS N/A
- YMAB N/A
- Industry
- GASS Marine Transportation
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GASS Consumer Discretionary
- YMAB Health Care
- Exchange
- GASS Nasdaq
- YMAB Nasdaq
- Market Cap
- GASS 185.5M
- YMAB 218.4M
- IPO Year
- GASS 2005
- YMAB 2018
- Fundamental
- Price
- GASS $5.46
- YMAB $4.10
- Analyst Decision
- GASS
- YMAB Buy
- Analyst Count
- GASS 0
- YMAB 11
- Target Price
- GASS N/A
- YMAB $18.73
- AVG Volume (30 Days)
- GASS 91.7K
- YMAB 276.3K
- Earning Date
- GASS 05-21-2025
- YMAB 05-06-2025
- Dividend Yield
- GASS N/A
- YMAB N/A
- EPS Growth
- GASS 38.69
- YMAB N/A
- EPS
- GASS 1.90
- YMAB N/A
- Revenue
- GASS $167,262,185.00
- YMAB $87,685,000.00
- Revenue This Year
- GASS N/A
- YMAB N/A
- Revenue Next Year
- GASS $3.49
- YMAB $21.10
- P/E Ratio
- GASS $2.81
- YMAB N/A
- Revenue Growth
- GASS 16.54
- YMAB 3.38
- 52 Week Low
- GASS $4.82
- YMAB $3.84
- 52 Week High
- GASS $8.84
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- GASS 49.73
- YMAB 40.35
- Support Level
- GASS $4.94
- YMAB $3.91
- Resistance Level
- GASS $5.37
- YMAB $4.93
- Average True Range (ATR)
- GASS 0.20
- YMAB 0.45
- MACD
- GASS 0.03
- YMAB -0.03
- Stochastic Oscillator
- GASS 91.49
- YMAB 16.25
About GASS StealthGas Inc.
StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.